{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:42:15Z","timestamp":1781883735658,"version":"3.54.5"},"reference-count":16,"publisher":"Centers for Disease Control MMWR Office","issue":"43","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm6543a3","type":"journal-article","created":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T14:45:42Z","timestamp":1478184342000},"page":"1189-1194","source":"Crossref","is-referenced-by-count":67,"title":["Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons \u2014 Advisory Committee on Immunization Practices, 2016"],"prefix":"10.15585","volume":"65","author":[{"given":"Jessica R.","family":"MacNeil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorry G.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Patton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael R.","family":"Ortega-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey W.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2016,11,4]]},"reference":[{"key":"key-10.15585\/mmwr.mm6543a3-201611031044-R1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"(No. RR-2)","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.mm6543a3-201611031044-R2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2012.04.005","article-title":"Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus.","volume":"161","author":"Lujan-Zilbermann","year":"2012","journal-title":"J Pediatr"},{"key":"key-10.15585\/mmwr.mm6543a3-201611031044-R3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/INF.0b013e318236c67b","article-title":"Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.","volume":"31","author":"Siberry","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.mm6543a3-201611031044-R4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/INF.0b013e3181c38f3b","article-title":"Phase I\/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.","volume":"29","author":"Siberry","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.mm6543a3-201611031044-R5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3201\/eid0701.010114","article-title":"Active bacterial core surveillance of the emerging infections program network.","volume":"7","author":"Schuchat","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"key-10.15585\/mmwr.mm6543a3-201611031044-R6","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1097\/QAD.0b013e32833a2520","article-title":"Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa.","volume":"24","author":"Cohen","year":"2010","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.mm6543a3-201611031044-R7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7326\/0003-4819-160-1-201401070-00731","article-title":"Elevated risk for invasive meningococcal disease among persons with HIV.","volume":"160","author":"Miller","year":"2014","journal-title":"Ann Intern Med"},{"key":"key-10.15585\/mmwr.mm6543a3-201611031044-R8","doi-asserted-by":"publisher","first-page":"297.","DOI":"10.1186\/s12916-015-0538-6","article-title":"Risk of invasive meningococcal disease in children and adults with HIV in England: a population-based cohort study.","volume":"13","author":"Simmons","year":"2015","journal-title":"BMC Med"},{"key":"key-10.15585\/mmwr.mm6543a3-201611031044-R9","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw226","article-title":"Meningococcal disease in patients with HIV infection\u2014a review of cases reported through active surveillance in the United States, 2000\u20132008","author":"Harris","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.mm6543a3-201611031044-R10","first-page":"527","article-title":"Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013.","volume":"63","author":"MacNeil","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm6543a3-201611031044-R11","first-page":"1018","article-title":"Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease\u2014Advisory Committee on Immunization Practices (ACIP), 2011.","volume":"60","author":"CDC","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm6543a3-201611031044-R12","first-page":"1391","article-title":"Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease.","volume":"60","author":"CDC","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm6543a3-201611031044-R13","unstructured":"Food and Drug Administration. Menveo U.S. package insert. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2013. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM201349.pdf"},{"key":"key-10.15585\/mmwr.mm6543a3-201611031044-R14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/INF.0b013e31823dce5c","article-title":"Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants.","volume":"31","author":"Klein","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.mm6543a3-201611031044-R15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.4161\/hv.27051","article-title":"Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age.","volume":"10","author":"Nolan","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.mm6543a3-201611031044-R16","unstructured":"Food and Drug Administration. Menactra U.S. package insert. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2016. http:\/\/www.fda.gov\/downloads\/BiologicBloodVaccines\/Vaccines\/ApprovedProducts\/UCM131170.pdf"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T02:43:38Z","timestamp":1498358618000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/65\/wr\/mm6543a3.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,4]]},"references-count":16,"journal-issue":{"issue":"43","published-online":{"date-parts":[[2016,11,4]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm6543a3","relation":{},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"value":"0149-2195","type":"print"},{"value":"1545-861X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,11,4]]},"published":{"date-parts":[[2016,11,4]]}}}